Along with previous seed investors, a group of new private investors, family offices and Ascenion participated in this round. The funding enables the company to roll-out its fully-automated ‘lab-in-a-box system’ consisting of the LabDisk-Analyzer and the PsorX-LabDisk, the first disk to go with the system, which enables the differential diagnosis of psoriasis and eczema. Further disks are being developed with an initial focus on skin cancer and chronic inflammatory skin diseases.
The outstanding precision and ease of use of Dermagnostix’ approach is set to close the gap between diagnostic and therapeutic advances in the field of dermatology. While therapies have become increasingly effective and specific over the last decades, diagnosis is still largely based on subjective visual examinations which make it hard to differentiate diseases with similar appearance and may lead to wrong therapy decisions.
The start-up builds on know-how and technology from Hahn-Schickard Institute in Freiburg, Helmholtz Munich and the Klinikum rechts der Isar of the Technical University of Munich. It gained collaborative support from Helmholtz Munich’s innovation management department, Ascenion and the Bayerische Patentallianz (BayPAT).
Revenues Ascenion may receive from the future sale of shares will be mostly distributed to the LifeScience Foundation, which in turn will make them available to its endowing institutes, including Helmholtz Munich as research grants.
Further information: